BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

19 related articles for article (PubMed ID: 38612758)

  • 1. Viral targeting of glioblastoma stem cells with patient-specific genetic and post-translational p53 deregulations.
    Gil-Ranedo J; Gallego-GarcĂ­a C; Almendral JM
    Cell Rep; 2024 May; 43(5):114213. PubMed ID: 38700980
    [No Abstract]   [Full Text] [Related]  

  • 2. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
    Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
    Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
    Song Y; Zhang L; Jiang Y; Hu T; Zhang D; Qiao Q; Wang R; Wang M; Han S
    Theranostics; 2019; 9(20):6019-6030. PubMed ID: 31534534
    [No Abstract]   [Full Text] [Related]  

  • 4. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.
    Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B
    Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
    Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
    Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells.
    Nakagawa-Saito Y; Mitobe Y; Togashi K; Suzuki S; Sugai A; Takenouchi S; Nakamura K; Sonoda Y; Kitanaka C; Okada M
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma.
    Stegh AH; DePinho RA
    Cell Cycle; 2011 Jan; 10(1):33-8. PubMed ID: 21200141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.
    Manfredi JJ
    Genes Dev; 2010 Aug; 24(15):1580-9. PubMed ID: 20679392
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.